Company / Capital Returned to Shareholders per Share
Gilead Sciences Capital Returned to Shareholders per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Returned to Shareholders per Share
$4.76
FY2025
5-year range
$3.33 / $4.76
FY2021-FY2025
Trend
+16.9%
vs FY2024
Sector context
#8 of 51
Health Care
What the data says
Gilead Sciences's capital returned to shareholders per share of $4.76 is higher than 84% of companies in the Health Care sector (FY2025). Capital Returned to Shareholders per Share has fluctuated over the past 10 years, ranging from $2.87 in FY2019 to $10.29 in FY2018.
Based on SEC 10-K filings.
4.76 in FY2025 with a 5-year CAGR of +3.7%. Top quartile in the Health Care sector.
Improved from $3.33 to $4.76 over the past 2 years.
Health Care sector context is included.
Capital Returned to Shareholders per Share over time
Growth rates
- 3-Year CAGR
- +5.8%
- 5-Year CAGR
- +3.7%
- 10-Year CAGR
- -
Sector benchmark
+73.8% above sector average
Key checks
Key Insights
- In FY2025, capital returned to shareholders per share increased 16.9% year-over-year.
- Ranks #8 out of 51 companies in the Health Care sector.
- Peak capital returned to shareholders per share was recorded in FY2018.
- Lowest capital returned to shareholders per share in the period was in FY2019.
Company context
Key Data Points
- Strong profit margin: 27.9%
- Strong return on equity: 37.6%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital Returned to Shareholders per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $4.76 | +16.9% |
| FY2024 | $4.07 | +22.2% |
| FY2023 | $3.33 | -17.0% |
| FY2022 | $4.01 | +1.2% |
| FY2021 | $3.96 | -0.3% |
| FY2020 | $3.97 | +38.3% |
| FY2019 | $2.87 | -72.1% |
| FY2018 | $10.29 | +13.5% |
| FY2017 | $9.07 | +141.0% |
| FY2016 | $3.76 | -52.5% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026